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in patients with idiopathic pulmonary fibrosis treated 
with nintedanib: a longitudinal cohort study
Abstract
Introduction: The Gender-Age-Physiology (GAP) system is a tool for predicting prognosis in patients with idiopathic pulmonary 
fibrosis (IPF). Yet, to date, the GAP system has not been evaluated in patients with IPF who received nintedanib. 
Material and methods: This single-center retrospective study included 89 patients with IPF who received nintedanib for at least 
3 months. All-cause mortality was set as the end point. Clinical parameters, including the GAP stage, were statistically analyzed 
for risk factors leading to mortality using the Cox proportional hazard model.
Results: The median follow-up was 16.4 months (range 3.7–37.4 months), during which 23 patients died. Univariate analysis 
revealed that the GAP stage (hazard ratio [HR] 3.00, 95% confidence interval [CI] 1.52–5.92, p = 0.0014) and PaO2 (HR 0.95, 95% 
CI 0.92–0.98, p = 0.0063) were significant prognostic factors. Multivariate analysis revealed that the GAP stage was a significant 
prognostic factor (HR 2.26, 95% CI 1.07–4.78, p = 0.031). Log-rank analysis revealed that there were no significant differences in 
“Gender” (p = 0.47) and “Age” (p = 0.18) factors. However, there were significant differences in “Physiology” factors (% of forced 
vital capacity, p = 0.018; % of diffusing capacity of lung carbon monoxide, p < 0.001). The cumulative incidences of mortality at 
1 and 2 years were as follows: GAP I: 5.1% and 6.8%; GAP II: 9.5% and 29.3%; and GAP III: 18.9% and 84.2%.
Conclusions: The GAP system is useful as a prognostic tool in patients with IPF who have been treated with nintedanib. 
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Introduction
Idiopathic pulmonary fibrosis (IPF) is 
a chronic progressive interstitial pneumonia [1]. 
IPF exhibits a poor prognosis similar to many 
types of cancers, with an average survival time 
of 2–3 years after diagnosis [2–4]. Pulmonary 
function tests are important in the evaluation 
of the severity of IPF [1, 4]. In pulmonary func-
tion testing, the forced vital capacity (FVC) and 
the diffusion capacity of lung carbon monoxide 
(DLCO) have been identified as important prognos-
tic factors in patients with IPF [2, 5, 6]. 
Nintedanib is a tyrosine-kinase inhibitor 
that targets vascular endothelial growth factor 
receptors, fibroblast growth factor receptors, and 
platelet-derived growth factor receptors [7, 8]. 
In the most recent international clinical practice 
guidelines, nintedanib received a conditional 
recommendation for the treatment of IPF [9]. It 
should be noted that although nintedanib was 
useful in patients with severe IPF who did not 
meet the eligibility criteria for clinical trials of 
nintedanib (INPULSIS-1/2 trial [10]), we previ-
ously reported that the prognosis of these patients 
was worse [11].
An accurate evaluation of a patient’s clinical 
severity combined with a theory regarding progno-
sis are both very important clinical issues in deter-
mining appropriate treatment. Several prognostic 
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factors for IPF have been reported including male 
gender [12], elderly age [13], %FVC at baseline 
[13–15], and %DLCO at baseline [14]. In addition, 
serum biomarkers (surfactant proteins A and D 
[16], C-C motif chemokine ligand 18 [15], and 
matrix metalloproteinase collagen fragments [17]) 
and gene polymorphisms (MUC5B promoter poly-
morphism [18]) have been reported as prognostic 
factors. However, as these biomarkers are difficult 
to measure in general hospitals, they are not always 
used as prognostic factors in clinical practice.
The Gender-Age-Physiology (GAP) system 
has been reported as a simple and useful tool 
for the prediction of prognosis in patients with 
IPF in several nationwide IPF registries (e.g., 
Germany, Australia, and South Korea) [19–22]. 
However, these registries include many patients 
who were registered prior to the increased use of 
antifibrotic drugs. Since 2015, antifibrotic agents 
(e.g., pirfenidone and nintedanib) have been rec-
ommended as treatments for IPF [9]. 
Recently, the GAP system was evaluated as 
a prognostic model in patients with IPF treated 
with pirfenidone [23–25]. However, to date, the 
GAP system has not been evaluated in patients 
with IPF who received other recommended anti-
fibrotic agents such as nintedanib. Therefore, in 
this study, we retrospectively examined whether 
the GAP system is useful as a prognostic model in 
patients with IPF who have received nintedanib.
Materials and methods
This single-center, retrospective study was 
performed in accordance with the amended 
Declaration of Helsinki. The research protocol 
was approved by the Human Ethics Committee 
of Chiba University Hospital (approval number: 
3481). We obtained informed consent with an 
option to opt out.
Patients
Overall, 142 consecutive patients received 
nintedanib in the Chiba University Hospital 
between November 2015 and December 2018. Pa-
tients who did not have IPF (n = 31), patients with 
lung cancer at the start of nintedanib (n = 8), and 
patients who received nintedanib for acute exac-
erbations (n = 3) were excluded. Of the remaining 
100 patients, 11 patients were excluded because 
they discontinued treatment within 3 months 
of starting therapy with nintedanib. Ultimately, 
89 patients with IPF were enrolled (Figure 1). IPF 
was diagnosed based on the American Thoracic 
Society/European Respiratory Society Thoracic 
Association/Japanese Respiratory Society (JRS)/
Latin American Thoracic Association IPF guide-
lines from 2018 [26].
GAP system
The GAP score was calculated according 
to the report by Ley et al. [19]: gender (female, 
0 points; male, 1 point), age (≤ 60 years, 0 points; 
61–65 years, 1 point; > 65, 2 points), %FVC (> 
75%, 0 points; 50–75, 1 point; < 50, 2 points), and 
%DLCO (> 55%, 0; 36–55, 1 point; ≤ 35, 2 points; 
cannot obtain DLCO, 3 points). The GAP stage was 
determined based on the total GAP score: stage 
I (0–3 points), stage II (4–5 points), and stage III 
(6–8 points).
JRS severity staging system
The JRS severity staging system consists of 
the combination of two known prognostic vari-
ables which are resting arterial partial pressure of 
oxygen (PaO2) and peripheral capillary oxygen sat-
uration (SpO2) in the 6-minute walk test (6MWT) 
Figure 1. Study flow chart. In total, 124 patients received nintedanib 
in our hospital between November 2015 and December 2018. Pa-
tients who did not have IPF (n = 26), with lung cancer at the start of 
nintedanib treatment (n = 6), and who received nintedanib for acute 
exacerbation stage (n = 3) were excluded. Of the remaining 92 pa-
tients, 12 were excluded because they discontinued treatment within 
3 months of nintedanib administration. Ultimately, 82 patients with IPF 
were enrolled (GAP stage I, n = 20; GAP stage II, n = 45; GAP stage 
III, n = 17). GAP — Gender-Age-Physiology stage; IPF — idiopathic 
pulmonary fibrosis
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[27]. The present severity staging system for IPF 
defines PaO2 ≥ 80 Torr at rest as stage I, 70–79 Torr 
as stage II, 60–69 Torr as stage III, and < 60 Torr 
as stage IV. If the SpO2 at the end of 6MWT is 
< 90%, then the severity should be increased by 
one stage for patients with stage II or III.
Statistical analysis
The clinical data regarding continuous vari-
ables are expressed as the mean ± standard 
deviation. The categorical variables are given as 
percentages. The Cox proportional hazard model 
analysis was used to identify significant factors for 
predicting patient mortality. Kaplan-Meier surviv-
al curves and log-rank tests were used to compare 
patient survival according to GAP stages. The level 
of significance [p value (p) < 0.05] was adopted 
as statistically significant. All statistical analyses 
were performed using the EZR software package 
(Saitama Medical Center, Jichi Medical University, 
Saitama, Japan) [28] and the graphical user inter-
face for R (R version 3.2.0, The R Foundation for 
Statistical Computing, Vienna, Austria).
Results
The baseline characteristics of the included 
patients (GAP I, n = 22; GAP II, n = 48; GAP III, 
n = 19) are shown in Table 1. The median dura-
tion of follow-up time, which started following 
3 months of treatment, was 16.4 months (range 
3.7–37.4 months). Twenty-three deaths (25%) 
were observed during the follow-up time (GAP 
I, n = 2 [9%]; GAP II, n = 11 [22%]; GAP III, n 
= 10 [52%]). The causes of death are shown in 
Table 2. Ten patients died of chronic pulmonary 
failure and eight patients died due to an acute 
exacerbation of disease. 
The log-rank test result revealed a significant 
difference in mortality among the three groups 
(GAP I, II, and III; p = 0.0013; Figure 2). The cu-
mulative incidences of mortality at 1 and 2 years 
were as follows: GAP I, 5.1 % and 6.8 %; GAP II, 
9.5 % and 29.3 %; and GAP III, 18.9 % and 84.2 %.
The survival curves drawn for each of the 
four factors comprising the GAP system (gender, 
age, %FVC, and %DLCO) are shown in Figures 
3–6. There were no significant differences be-
tween male and female patients (p = 0.47; Figure 
3), or among the three age groups (p = 0.18; Figure 
4). There was a significant difference among the 
three groups in %FVC (p = 0.018; Figure 5) and 
%DLCO (p < 0.001; Figure 6).
The log-rank test result also revealed a sig-
nificant difference in the survival of patients who 
were not admitted for hospital care among the 
Table 1. Baseline characteristics of 89 included patients
Total (n = 89) GAP I (n = 22) GAP II (n = 48) GAP III (n = 19)
Age 71.3 ± 6.2 70.3 ± 5.4 71.6 ± 7.0 71.5 ± 4.6
Male, n (%) 68 (76%) 15 (68%) 39 (81%) 14 (73%)
Smoker, n (%) 68 (76%) 15 (68%) 38 (79%) 15 (78%)
BMI (kg/m2) 23.8 ± 4.0 23.9 ± 4.0 23.9 ± 4.1 23.4 ± 3.7
Severity staging system in JRS (I/II/III/IV) 29 / 4 / 26 / 30 13 / 1 / 5 / 3 14 / 2 / 17 / 15 2 / 1 / 4 / 12
UIP pattern in HRCT 66 (74%) 13 (59%) 37 (77%) 16 (84%)
Pre-treatment with PFD 32 (35%) 4 (18%) 15 (31%) 13 (68%)
Long-term home oxygen therapy 23 (25%) 3 (13%) 9 (18%) 11 (57%)
PaO2 (mm Hg) 73 ± 13 81 ± 13 73 ± 12 63 ± 11
Minimum SpO2 by 6MWT (%) 80 ± 9 83 ± 10 80 ± 7 75 ± 12
KL-6 (U/mL) 1421 ± 1114 1252 ± 953 1323 ± 1106 1889 ± 1242
FVC (mL) 2172 ± 802 2735 ± 833 2129 ± 706 1601 ± 544
%FVC (%) 67 ± 19 86 ± 17 64 ± 14 50 ± 11
%DLCO (%) 56 ± 21 71 ± 9 54 ± 22 32 ± 7
Follow-up duration, median [range] (month) 16.4 [3.7–37.4] 16.5 [4.5–33.9] 18.1 [3.7–37.4] 12.5 [4.0–36.0]
Death, n (%) 23 (25%) 2 (9%) 11 (22%) 10 (52%)
6MWT — 6 minutes walk test; BMI — body mass index; DLCO — diffusing capacity of the lungs for carbon monoxide; FVC — forced vital capacity; GAP — Gender 
Age-Physiology; HRCT — high-resolution computed tomography; JRS — Japan respiratory society; KL-6 — Krebs von den Lungen-6; PFD — pirfenidone; UIP — usual 
interstitial pneumonia
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Figure 2. Survival curves of GAP stages I, II, and III. The log-rank test 
result reveals a significant difference in mortality among the three 
groups (GAP I, II, and III) (p = 0.0013). GAP — Gender-Age-Physi-
ology stage.
Figure 3. Survival curves between male and female patients. The log-
rank test result reveals no significant difference between male and 
female patients (p = 0.40)
Table 2. Cause of death
Total (n = 89) GAP I (n = 22) GAP II (n =4 8) GAP III (n = 19)
Death, n (%) 23 (25%) 2 (9%) 11 (22%) 10 (52%)
Chronic pulmonary failure 10 0 6 4
Acute exacerbation 8 0 4 4
Lung cancer 2 1 1 0
Pneumonia 3 1 0 2
GAP — Gender-Age-Physiology
Figure 4. Survival curves of the three age groups. The log-rank test 
result reveals no significant difference among the three age groups 
(p = 0.14). Y.o. — years old
Figure 5. Survival curves of the three groups of %FVC. The log-rank 
test result reveals a significant difference among the three groups of 
%FVC (p = 0.015). %FVC — percentage of forced vital capacity
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three groups (GAP I, II, and III; p = 0.033; Figure 7). 
The cumulative incidence of admission or death 
at 1 and 2 years were as follows: GAP I, 5.1% 
and 6.8%; GAP II, 14.9% and 34.6%; and GAP 
III, 46.8% and 91.5%.
Univariate analysis revealed that the GAP 
stage [hazard ratio (HR) 3.00, 95% confidence 
interval (CI) 1.52–5.92, p = 0.0014], PaO2 (HR 
0.95, 95% CI 0.92–0.98, p = 0.0063), and long-
term home oxygen therapy (HR 2.72, 95% CI 
1.17–6.28, p = 0.018) were significant risk factors 
(Table 3). Additionally, the %FVC (HR 0.96, 95% 
CI 0.93–0.98, p = 0.0042) and the %DLCO (HR 0.93, 
95% CI 0.90–0.97, p < 0.001), which constitute 
the GAP stage, were demonstrated as significant 
risk factors. Multivariate analysis with the GAP 
stage, PaO2, and body mass index (BMI), which 
had low p-values in the univariate analysis, 
showed that the GAP stage (HR 2.26, 95% CI 
1.07–4.78, p = 0.031) and BMI (HR 0.89, 95% CI 
0.80–0.99, p = 0.048) were significant prognostic 
factors (Table 3).
Discussion
To the best of our knowledge, this is the first 
study to demonstrate that the GAP system, which 
is a prognostic model for patients with IPF, also 
has prognostic value in patients with IPF that had 
been treated with the antifibrotic agent nintedanib 
(Figure 2). In Japan, the JRS severity system is 
a classification system based on PaO2 and the low-
est SpO2 in the 6MWT. In the present study, we 
found that while PaO2 was a significant prognos-
tic factor in univariate analysis, the JRS severity 
system was not (Table 3). Moreover, multivariate 
analysis revealed that the GAP system and BMI 
were also significant prognostic factors. The GAP 
system has been reported as a simple and useful 
tool for the prediction of prognosis in patients 
with IPF [19], However, the use of the GAP sys-
tem as a prognostic model was proposed before 
the widespread use of antifibrotic drugs for IPF 
treatment. Therefore, it was potentially less use-
ful in the context of antifibrotic drug treatment. 
Recently, the GAP system has been validated as 
a prognostic model for patients with IPF receiving 
the antifibrotic drug pirfenidone [23–25]. Our 
current results confirm these findings and sug-
gest that the GAP system is also an appropriate 
prognostic model for patients with IPF receiving 
the antifibrotic drug nintedanib.
In this study, %FVC was the strongest prog-
nostic factor among the four items evaluated in 
the GAP system. The effects of age and gender 
were weaker than those of %FVC and %DLCO 
(Figures 3–6). We found no significant differences 
in sex (HR 0.72, 95% CI 0.29–1.76, p = 0.47) in 
the univariate analysis, although male patients 
tended to have a better prognosis (Figure 3). In 
the original report of the GAP system by Ley et al. 
[19], sex had a lower impact on prognosis com-
pared with other factors. Although mortality due 
to IPF was initially reported to be higher in men 
[12], a recent study by Song et al. [29] found that 
among 380 patients with IPF, survival time was 
nearly equivalent between male (46.6 months) 
and female (45.0 months) patients (Chi-squared 
Figure 6. Survival curves of the three groups of %DLCO. The log-rank 
test result reveals a significant difference among the three groups of 
%DLCO (p < 0.001). %DLCO, diffusing capacity of lung carbon monoxide
Figure 7. Admission-free survival curves of GAP stages I, II, and III. 
The log-rank test result reveals a significant difference in admission 
free survival time among the three groups (GAP I, II, and III) (p = 
0.033). GAP — Gender-Age-Physiology stage
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Table 3. Univariate and multivariate analysis of survival
Univariate analysis Multivariate analysis
HR 95% CI p-value HR 95% CI p-value
Age 0.98 0.93–1.04 0.63
Male 0.72 0.29–1.76 0.47
Smoker 0.96 0.35–2.60 0.94
BMI 0.90 0.82–1.00 0.056 0.89 0.80–0.99 0.048
Severity staging system in JRS 1.37 0.95–1.99 0.091
GAP stage 3.00 1.52–5.92 0.0014 2.26 1.07–4.78 0.031
UIP pattern in HRCT 2.30 0.68–7.77 0.17
Pre-treatment with PFD 1.47 0.88–2.45 0.13
Long-term home oxygen therapy 2.50 1.10–5.68 0.027
PaO2 0.95 0.92–0.98 0.0063 0.97 0.93–1.00 0.11
Minimum SpO2 by 6MWT 0.96 0.93–1.00 0.061
KL-6 1.00 0.99–1.00 0.91
FVC 0.50 0.27–0.90 0.022
%FVC 0.96 0.93–0.98 0.0042
%DLCO 0.95 0.92–0.98 0.0023
6MWT — 6 minutes walk test; BMI — body mass index; CI — confidence interval; DLCO — diffusing capacity of the lungs for carbon monoxide; FVC — forced vital 
capacity; GAP — Gender-Age-Physiology; HR — hazard ratio; HRCT — high-resolution computed tomography; JRS — Japan Respiratory Society; KL-6 — Krebs von 
den Lungen-6, UIP — usual interstitial pneumonia; PFD — pirfenidone
test, p = 0.887). These findings are consistent 
with the outcome of our study and together sug-
gest that the administration of nintedanib does 
not affect the relationship between gender and 
prognosis. 
In the present study, elderly people (> 65 years) 
did not have a worse prognosis than young peo-
ple (≤ 60 years). While Song et al. [29] reported 
that younger patients (< 50 years) tended to have 
a good prognosis compared to that of elderly 
patients (> 75 years), the difference was not sig-
nificant (Kolmogorov-Smirnov test, p = 0.268). 
One potential reason for this difference is due 
to nintedanib’s high frequency of side effects 
(e.g., diarrhea, anorexia, liver injury) [10]. El-
derly patients with a poor general condition 
might not have received nintedanib due to their 
attending physician’s preferences. This may 
have affected the assessment of differences in 
prognosis by age.
In this study, the cumulative incidences of 
mortality at 1 and 2 years were as follows: GAP 
I, 5.1% and 6.8%; GAP II, 9.5% and 29.3%; and 
GAP III, 18.9% and 84.2%, respectively. These 
results are similar to those reported by Harari et 
al. [25] in their study of patients who received pir-
fenidone (GAP I, 8.4% and 17.2%; GAP II, 17.6% 
and 34.2%; and GAP III 28.3% and 51.2%, respec-
tively) thus indicating the validity of the present 
study. Together, these findings also suggest that 
the therapeutic effects obtained by nintedanib 
and pirfenidone might be similar. 
Notably, our results showed that patients 
with GAP stage III have an extremely poor prog-
nosis. Therefore, it is desirable to start treatment 
of these patients immediately. However, our 
results indicate that for patients with IPF with 
GAP stage I/II, it is also important to start early 
treatment with antifibrotic drugs. In the origi-
nal report of the GAP system by Ley et al., [19] 
the cumulative incidences of mortality at 1 and 
2 years were as follows: GAP I, 5.6% and 10.9%; 
GAP II, 16.2% and 29.9%; and GAP III 39.2% and 
62.8%. Although obtaining a direct comparison 
between the studies is difficult due to differences 
in patient background, the overall mortality rate 
in the present study tended to be better than that 
reported by Ley et al. [19]. However, it should 
be noted that the 2-year mortality rate for GAP 
III patients was higher in the present study. The 
long-term effects of nintedanib in patients with 
advanced IPF are unknown and should be clari-
fied in further studies.
Our study revealed that the GAP system is not 
only a prognostic model, but also an appropriate 
predictive model of survival in non-admitted pa-
Mitsuhiro Abe et al., GAP stage in IPF treated with nintedanib
375www.journals.viamedica.pl
tients with IPF who were receiving the antifibrotic 
drug nintedanib (Figure 7).
This study had some limitations. Firstly, the 
study had a retrospective, single-center design 
with a small sample size. Secondly, the median 
follow-up duration was short. Therefore, in the 
future, it will be necessary to demonstrate the 
usefulness of the GAP system in patients receiving 
antifibrotic drugs in a large-scale, nationwide, 
prospective study.
Conclusions
The GAP stage is useful as a prognostic tool 
in patients with IPF who have been treated with 
nintedanib. The physiological parameters of the 
GAP system (%FVC and %DLCO) are of particular 
importance with regard to patient prognosis.
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